The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised xenogeneic transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection.

A invenção do presente caracteriza um modelo animal non-human que seja suscetível à infecção pelos pathogens hepatotrophic humanos, particularmente vírus humano do hepatitis C (HCV). O modelo é baseado em um non-human, immunocompromised o animal transgenic xenogeneic que tem um fígado chimeric do humano-rato, onde o transgene forneça para a expressão de um urokinase-tipo activador plasminogen no fígado. A invenção caracteriza também métodos para identificar agentes therapeutic do candidato, por exemplo, agentes que têm a atividade antiviral de encontro à infecção de HCV.

 
Web www.patentalert.com

< Anti-HCV nucleoside derivatives

< Hepatitis C virus culture system

> Vaccine composition for preventing or treating hepatitis C

> Self-enhancing, pharmacologically controllable expression systems

~ 00058